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Low back pain (LBP) is a common problem encountered by physicians. It is a considerable cause of morbidity and socioeconomic
loss and is one of the most expensive musculoskeletal disorders. Conventional treatments include bed rest, analgesics, therapeutic
exercises, lumbar or caudal epidural corticosteroids, and surgery. Several new biological therapies are being investigated for use in
LBP and one of these is platelet-rich plasma (PRP). In this article, we summarize the current literature published on PRP concerning its
composition, classification, and application in LBP. We believe our review will prove useful to clinicians and academics alike, interested in new developing therapies for LBP.
Keywords: Platelet-rich plasma; Low back pain; Radiculopathy; Epidural

Introduction
Low back pain (LBP) is a common problem and a significant cause of morbidity and socioeconomic loss to society
[1]. It is the second leading cause of disability in American adults and one of the main reasons why people under
45-years limit their physical activity [2-4]. It imposes a
considerable disease burden on society and is one of the
most expensive musculoskeletal disorders [5].
When assessing patients with LBP, it is important to
look for radicular symptoms such as radiating leg pain,
sensory deficits, and neurologic lower limb deficits such

as motor weakness, and altered reflexes. Many factors
contribute to this pathological process. These include disc
degeneration leading to herniation, facet arthropathy,
ligamentum flavum hypertrophy, ossification of the posterior longitudinal ligament, congenitally narrow neural
foramen, ligament laxity, and subluxation [6]. Advancing
age contributes to these pathological processes and it is
logical to assume that with the increase in life expectancies globally, the incidence of LBP will also increase [7].
Patients with LBP can often be managed conservatively
with a combination of pharmacological and nonpharmacological therapies without the need for surgical or inva-
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sive procedures [2]. Conservative treatment includes bed
rest, analgesic medications such as nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen, muscle
relaxants, oral or parenteral steroids, and opioids as well
as therapeutic exercises [1,2]. Should these fail, lumbar or
caudal epidural glucocorticoid injections can be administered for pain management. Surgery is indicated, in cases
of pain refractory to conservative treatment or if neurological deficits develop.
New biological therapies are being investigated for use
in LBP. One such treatment is the use of platelet-rich
plasma (PRP). PRP is plasma containing concentrated
platelets acquired from autologous blood. Advocates of
PRP call it a bridge between conservative therapy and surgery. Platelets are rich in cytokines and growth factors and
these are believed to accelerate the body’s repair processes.
They could, therefore, be beneficial for treating the inflamed nerves in lumbar radiculopathy and canal stenosis.
The purpose of this article is to provide a review of the
currently available literature concerning the use of PRP in
lumbar spine pathologies that lead to LBP. We hope this
will prove useful to clinicians and academics interested in
developing new therapies for LBP.

What is Platelet-Rich Plasma?
PRP is a sequestration of platelets in the plasma fraction
of autologous blood, which when activated by an exogenous agent releases a host of mediators and growth factors
[8-14]. Normal platelet counts in the blood range from
150,000/μL to 350,000/μL. PRP, however may contain
platelet concentrations of up to 1,000,000/μL [14]. It is this
concentration in 5 mL of autologous plasma that is considered to be the practical definition of PRP [9]. However
different concentrations and volumes are used in practice.
PRP was first used in dental implant procedures [9]. Its
use since then has been extended to areas such as oral and
maxillofacial surgery, cardiovascular surgery, spine surgery, plastic surgery, podiatric surgery, pulmonary care,
and advanced wound care [10].

Composition of Platelet-Rich Plasma
Platelets are anucleate cell fragments derived from megakaryocytes in the bone marrow [10]. They contain organelles such as mitochondria, ribosomes, lysosomes, and
two types of granules, alpha and dense.
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Each platelet has about 50 to 80 alpha granules [10].
Alpha granules contain more than 300 different proteins
[15]. Dense granules, on the other hand, are relatively
few in number and contain important chemicals such as
calcium, serotonin, histamine, and different phosphate
compounds such as adenosine diphosphate, adenosine
triphosphate, and guanosine diphosphate [16].
Platelets are a storehouse of important growth factors
such as platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-β), insulin-like growth factor 1, vascular endothelial growth factorm and epithelial
growth factor [9,10,14,17]. When released from degranulated platelets they mediate healing and play important
roles in chemotaxis and migration, angiogenesis, and
cell proliferation and differentiation. All these processes
ultimately lead to repair [17]. There are also several cytokines, chemokines, and metabolites released by activated
platelets that further supplement these actions [17].
Depending on the preparation technique, PRP may or
may not contain leukocytes. Leukocytes are thought to
release metalloproteinases and free radicals which may be
counterproductive to the repair process and may also increase postinjection pain [9,18]. However, they may exert
antimicrobial actions [19] and some researchers believe
that leukocytes have crucial repair mediating enzymes as
well [18].

Preparation of Platelet-Rich Plasma
Blood is first drawn from the patient at the time of treatment. An anticoagulant is used to prevent premature
activation of the platelets [20]. The blood sample is centrifuged to separate the components into different layers
one of which is formed by the PRP. The volume of PRP directly correlates to the baseline platelet count [21]. At this
stage, one of two methods can be used to complete the
preparation; the PRP method or the buffy coat method.

Platelet-Rich Plasma Method
Blood is initially centrifuged at a constant acceleration
(“soft spin”) to concentrate platelets in the supernatant.
The platelet-containing plasma is then separated into a
sterile tube and centrifuged at a higher speed (“hard spin”)
for the second time to acquire the platelet concentrate.
This step leads to the creation of the PRP (lower one-third
the platelet concentrate) and platelet-poor plasma (PPP)
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(the upper two-thirds of the platelet concentrate) [20].

Buffy Coat Method
The whole blood must initially be stored at a cool temperature (range, 20°C to 24°C) before centrifugation [20].
High-speed centrifugation of the whole blood sample
forms three layers; a superficial layer (PPP), an intermediate layer also called the “buffy coat” (platelets and
white blood cells [WBCs]) and a deep layer consisting of
red blood cells (RBCs). The buffy coat is then separated
and centrifuged at a lower speed, yielding a layer of PRP,
which is separated from the resulting solution [20,21].

Classification of Platelet-Rich Plasma
A standardized classification of PRP will increase the
standardization of PRP reporting and the resultant data
comparability. A wide range of classification systems have
been recommended by different authors but the four main
classification systems are mentioned below.
Mishra et al. [22] categorize PRP preparations into four
main types depending on the concentration of PRP, the
WBC content, and the activation status. Type 1 and type
2 PRP have WBC levels that are higher than the baseline.
They differ in their activation status by an exogenous activator, such as calcium or thrombin. Type 2 is activated
whereas type 1 is not. Similarly, type 3 and type 4 PRP
have minimal WBCs and type 3 is not activated by an
exogenous activator while type 4 is. Each group is then
further subdivided based on the platelet concentration. If
it is over 5 times higher than the baseline it is classed as
subgroup A, if not, it is in subgroup B. Mishra’s classification was acceptable for PRP preparations available in 2006
[13]. Mautner et al. [13], however, deem it insufficient as
advancing technology, such as the development of double
spin suspension systems, has allowed higher concentrations of platelets, with little or no neutrophils and RBCs in
the PRP.
In 2009, Dohan Ehrenfest et al. [23,24] published another system, which classified PRP according to its platelet
and leukocyte concentration and the absence or presence
of fibrin. PRP was divided into pure PRP; leukocyte and
PRP; pure platelet-rich fibrin (PRF); and leukocyte and
PRF [23,24]. According to Mautner et al. [13], this approach is limited by its inability to be applied in nonoperative conditions due to the limited use of fibrin and the
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Table 1. PLRA classification system proposed by Mautner et al. [13]

PLRA classification

Criteria

P: platelets count

_____P
Volume injected

_______M
Cells/microlitter

L: leukocyte contenta)

>1%

+

<1%

-

>1%

+

<1%

-

Yes

+

No

-

b)

R: red blood cell content
A: activation

PLAR, platelet, leukocyte, red blood cells, and activation.
a)
If white blood cells are present (+), the percentage of neutrophils should be
reported. b)The method of exogenous activation should be reported.

lack of information on RBC and WBC concentrations.
The “PAW” classification system was proposed by DeLong et al. [25] in 2012. This classification is based on the
concentration of platelets, the activation status, and the
WBC and neutrophil content relative to baseline [25]. The
concentration of platelets ranged from P1 (baseline) to P4
(>1.2 million platelets/mL). Activation was either exogenous or nonexogenous and WBCs and neutrophils above
or below baseline [25]. Mautner et al. [13], however, argue
that this classification also failed to include RBCs and its
categorization of WBCs and neutrophils into above and
below baseline greatly underestimated their roles in PRP
action.
In 2015, Mautner et al. [13] introduced their own classification system—the platelet, leukocyte, RBCs, and activation (PLRA) system. They classified PRP according to the
following parameters [13]: (1) the concentration of platelets, the total number of platelets and injected volume; (2)
the concentration of leukocytes; (3) the concentration of
RBC; and (4) activation by exogenous agents. The features
of the PLRA classification are summarized in Table 1.

Intra Facet and Ligament Injections
Facet joints have been implicated in 40% of cases of spine
pain [6]. However, we found only three studies that investigated the results of PRP injections into the facet joints and
the surrounding ligaments. Aufiero et al. [6] published a
case series of five patients in 2015. PRP was injected bilaterally at multiple levels of the cervical spine of two patients.
Two patients received PRP injections bilaterally in their
lower lumbar levels and one patient had injections in the
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lower thoracic and upper lumbar levels. PRP was injected
into the facet joints, capsule, supraspinous, and infraspinous ligaments under ultrasound or fluoroscopic guidance.
All five cases reported a significant improvement in their
pain. However, given the absence of a control group, it is
not possible to conclude whether this treatment is better or
worse than the established modalities.
Another study enrolled 19 patients with lumbar facet
joint syndrome and injected autologous PRP into the
lumbar facet joints under X-ray fluoroscopic guidance
[26]. Pain control outcomes were measured using the Visual Analog Scale (VAS), Roland–Morris Disability Questionnaire (RMQ), Oswestry Disability Index (ODI), and
modified MacNab criteria. Significant pain reduction was
experienced by nine patients (47.37%) immediately after
treatment, 14 (73.68%) at 1 week, and 15 patients (78.95%)
at 1 month, 2 months, and 3 months [26].
In 2017, a prospective comparative study randomized
46 patients into group A (intra-articular PRP) and group
B (intra-articular local anesthetic and corticosteroid) [27].
Pain outcomes were measured using VAS, RMQ, ODI,
and modified MacNab criteria. Both groups achieved
statistically significant pain relief. Subjective satisfaction
based on the modified MacNab criteria and the objective success rate for group B peaked (80% and 85%) after
1 month, but it was only 50% and 20% after 6 months.
However, for group A, they increased over time. It was
hence concluded that autologous PRP is a superior treatment option for longer duration efficacy [27]. This study
addressed the previous two studies’ lack of control group;
however, it was limited by the small number of patients.
More studies, with larger sample sizes and double-blinding, are needed for conclusive evidence.

Epidural Injections
Epidural steroid injections (ESIs) are an established
method of pain management in lumbar radiculopathy. In
fact, ESIs are the most widely performed pain management procedure in the world [28]. Their use has been
documented and corroborated by more than 45 placebocontrolled trials and dozens of systematic reviews [28].
They may be injected trans foramen, intralaminar, or caudally via the sciatic hiatus. The trans foramen approach
has shown to be the most efficacious as it is more targetspecific, has greater ventral epidural spread and is associated with lower chances of dural puncture [28].
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Steroids work by inhibiting the arachidonic acid cascade thereby limiting inflammation of the lumbar nerve
roots. Risk factors for this procedure include hemorrhage
or hematoma formation, infection, paralysis, or spinal
headache [4,10]. Steroid injections have also been implicated in spinal cord embolisms and septic and aseptic
meningitis [4,10].
The injection of PRP into the epidural space for lumbar radiculopathy is uncharted territory. In our literature
search, we were able to find only two papers describing
the injection of PRP in place of steroids.
The first study was a pilot study published in 2016 by
Bhatia and Chopra [4]. Using the intralaminar approach,
they injected 5 mL of PRP into the epidural spaces of 10
patients. Patients were followed up using the modified
Oswestry Disability Questionnaire (MODQ), Straight Leg
Raising Test (SLRT), and VAS scores. All patients showed
sustained improvement up to the 3-month follow-up period. VAS scores for all patients were 4 or less except for one
patient who scored 5. Most of the patients also showed an
improvement in MODQ and SLRT to less than 30% and
greater than 70, respectively.
The second paper was a case study published by Lemper
et al. [10]. They report a 35-year-old female being chronically managed for neck pain and LBP with radiation into
her arms and legs. She had a history of a motor vehicle
collision, after which these symptoms arose. She had received multiple cervical and lumbar ESIs which gave her
only a few weeks of relief before her pain returned. She
had also undergone 6 months of physical therapy with no
reported improvement in her symptoms.
She then became pregnant and the injections were
abandoned as steroids can lead to pregnancy complications, prolonged labor, and in severe cases fetal and maternal death [10]. She agreed to epidural PRP injections and
reported improvements in both her neck and lower back
pain. There were no adverse effects of the treatment on
the pregnancy and the patient delivered a healthy child.
Though both articles report positive results of epidural
PRP injections, there is a need for further studies before
wider use. Comparative studies with conventional therapies such as NSAIDs, physical therapy, and epidural steroids would help determine the efficacy of PRP compared
to that of already established modalities.
A significant limitation of epidural PRP is that patients
may not achieve acute pain relief. For this Bhatia and
Chopra [4] suggest the supplementation of PRP with

Asian Spine Journal
painkillers. Again, more studies are required to evaluate
this.

Intradiscal Injections
An intervertebral disc (IVD) is a pad of cartilage between
two adjacent vertebrae that acts as a shock absorber. It
plays a vital role in stabilization as well as flexion and extension of the spine [29].
Being the largest avascular structure in an adult human,
the IVD depends upon passive diffusion from the endplate vessels for nutrition. It is supplied by branches of the
metaphyseal arteries around the outer annulus [30]. Since
the IVD lacks a proper nutritional supply of growth factors, it has minimum self-repairing ability [29,31].
Degenerative disc disease (DDD) involves the degeneration of one or more IVDs [32] and depends upon genetic
and environmental factors [31]. The patient presents with
pain that may radiate [32]. Current treatment options include conservative approaches such as anti-inflammatory
drugs and physiotherapy, as well as spinal surgery [29].
Not only do current treatments completely ignore the underlying cause but treatment options like surgery restrict
patient mobility and can interrupt their daily activity for
nearly 6 weeks [32]. An alternative therapy like stem cells
or growth factors might be a possible cheap solution to
treat this pathology. It can be performed in outpatient
facilities and takes very little time [5]. The purpose of
intradiscal injections is to supply a high concentration of
growth factors to poorly nourished IVD for growth and
repair.
Several studies investigating the use of PRP on IVDs
have been published [29-33] (Table 2). Obata et al. [31]
induced disc degeneration in 12 rabbits by an annular
puncture in two noncontiguous discs. This produced
disc narrowing within 4 weeks. Autologous PRP or PPP
were isolated from fresh blood. Releasate isolated from
clotted PPP or PRP or phosphate-buffered saline (PBS)
control was injected at the site of the degenerating disc.
It was found that PRP releasate produced a statistically
significant restoration of disc height. The PRP treatment
group also had a higher number of chondrocyte-like cells.
However, magnetic resonance imaging (MRI), T2 quantification did not show a statistical difference in mean T2
values of nucleus pulposus and annulus fibrosus among
the three groups.
Another article demonstrates a similar finding. PRP was
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used with bone marrow-derived mesenchymal cells (BMSCs). A total of 30 rabbits were used in this experiment:
10 were in the PRP–BMSC group, 10 were injected with
PRP or PBS, while another 10 were given no intervention
and served as controls. MRI revealed the reparative effect
of PRP in the PRP–BMSC group and PRP group. On the
other hand, disc degeneration was unaffected in the PBS
group. MRI results at 8 weeks demonstrated a statistically
significant improvement in disc restoration in the PRP–
BMSC group as compared with other groups. The study,
therefore, indicates better efficacy of PRP if used together
with BMSCs [29].
Moving on to clinical studies, Comella et al. [32] report
a study on 15 patients undergoing liposuction to extract
mesenchymal cells. PRP was used with the adipose tissue
for IVD injections. The results indicated a statistically significant improvement in flexion (pelvis, lumbar, and total
flexion), pain, VAS, present pain intensity, and the scores
of other questionnaires. There were no serious complications. ODI and Beck Depression Inventory scores showed
improvement but with no statistical significance. The Dallas Pain Questionnaire showed an improvement in daily
and work and leisure activities. However, there was an
increase in anxiety and depression scores and a drop in
social interest. The study, however, lacked a control group
and further investigation is required. Levi et al. [33] state
a similar finding in another prospective trial involving 22
patients with discogenic LBP who were treated with PRP
IVD injections. The therapy was considered successful
if the patients managed a 30% improvement in ODI and
50% improvement in VAS after the 1 month, 2 months,
and 6 months following the injection. At 6 months, 47%
had a successful outcome in ODI and 41% had a successful outcome in VAS according to the criteria set. The trial
showed encouraging preliminary data supporting the use
of intradiscal PRP injections. This study also lacked a control group.
Another study conducted by Tuakli-Wosornu et al. [30]
consisted of adult patients with chronic (≥6 months),
moderate-to-severe lumbar discogenic pain that was
unresponsive to conservative treatment. The 58 study
participants were randomized to receive intradiscal PRP
or contrast agent after provocative discography. In the
PRP group, 56% were satisfied with the treatment compared with 17% of the control group. Those who received
PRP maintained their Functional Rating Index for 1 year.
There were no side effects or complications such as disc

Autologous PRP

To determine the in-vivo
reparative effects of
autologous PRP on IDD

To evaluate efficacy and
safety of intra-disc administration of SVF and
PRP into patients with
IDD

To assess the efficacy of
intra-disc PRP injection
in patients with low
back pain due to IDD

Obata et al. [31]
(2012)

Comella et al. [32]
(2017)

Levi et al. [33]
(2016)

22 Patients older than 18 years of age were chosen with low back pain
with intensity of at least 40 mm on a 0 to 100 mm on VAS. There was
no control group.
All patients were injected with PRP solution.
Follow-up VAS and ODI were held at 1, 2, and 6 months.

15 Patients ranging from the ages 18–90 years with diagnosed IDD were
included in the study. SVF-PRP solution was injected directly into the
NP. There was no control group.
Patients were evaluated at 2 and 6 months for the following parameters:
physical parameters: height, weight, vital signs, and low back range of
motion measured using an inclinometer; psychometric analysis: VAS
score, BDI, ODI, PPI, SM-MPQ, and SF-12.

IDD was induced with annular punctures at two noncontiguous discs.
12 Rabbits were divided into two groups: (1) treatment group: PRP and
PPP (n=8) received both PRP and PPP injections randomly; (2) control
group: PBS group (n=4) received PBS injection.
12 Weeks after the initial puncture, the spinal columns (L1 to L6 vertebra)
were isolated and subjected to quantitative T2 MRI analysis as well as
histologically evaluated via Safranin-O staining.

47 Patients older than 18 years of age with refractory low back pain were
divided into two groups: treatment group (n=29) received intra-disc PRP;
control group (n=18) received contrast agent.
Follow-up visits were scheduled at a week, 4 weeks, 8 weeks, 6 months,
and 1 year after PRP administration.
Parameters used in follow-up: FRI, NRS for pain, the pain and physical
function domains of the 36-item Short Form Health Survey, and the
modified NASS Outcome Questionnaire.

Early IDD was induced in all subjects with annular punctures seen as decreased T2-weighted signal intensity as seen on MRI.
40 Rabbits were divided into four groups: treatment group: (1) PRP-BMSC
group (n=10) received a combination of PRP and BMSC in order to test
the longevity of the reparative effect; control groups: (2) PRP group (n=10)
received PRP only injections; (3) PBS group (n=10) received PBS injections; and (4) no intervention group (n=10) received no intervention.
Histological evaluation was carried out via analyzation of T2-weighted
signal intensity of the targeted discs with the use of MRI at weeks 1, 2,
and 8.

Methodology

At 6 months, 47% showed improvement in the disability (ODI score).
At 6 months, 63% showed an improvement on the VAS of at least 20
mm with 41% achieving a successful outcome in VAS.

Statistically significant improvement in flexion (pelvic, lumbar, and total
flexion), VAS, and PPI.
ODI and BDI scores showed improvement but with no statistical significance.
Statistically significant improvement in outcome observed through SMMPQ; however, none was observed through SF-12 at both 2 and 6
months of follow-up.
Safety analysis: absence of severe adverse events was reported during
a 12-month follow-up period.

PBS group: T2 MRI analysis: decreased T2 signals compared to PRP and
PPP groups; histological evaluation: degenerated discs with loss of NP
content.
PRP and PPP groups: T2 MRI analysis: although increased T2 signals
were observed in NP and AF, this was not statistically significant;
histological evaluation: a statistically significant increase in the number of chondrocyte-like cells (p <0.01) in NP and AF in the PRP group
compared to PBS and PPP groups.

Among the PRP group, 56% were satisfied with the treatment compared
with 17% of the control group.
Statistically significant improvements were observed in the treatment
group (compared to control groups) on the following scales: NRS
(p =0.02), FRI (p =0.03), and NASS Outcome Questionnaire (p =0.01).
No adverse events were reported following the injection of PRP.

PRP group: a regenerative effect observed at weeks 1 and 2 following
treatment, seen as increased signal intensity on MRI. However, at
week 8, PRP group exhibited decreased signal intensity.
PBS group: continuous T2 signal loss during the 8-week period.
PRP-BMSC group: statistically significant disc restoration in the PRPBMSC group as compared with other groups over the 8- week period.

Results

PRP, platelet-rich plasma; BMSC, bone marrow-derived mesenchymal stem cells; IDD, intervertebral disc degeneration; MRI, magnetic resonance imaging; PBS, phosphate-buffered saline; FRI, Functional Rating Index; NRS,
Numeric Rating Scale; NASS, North American Spine Society; PPP, platelet-poor plasma; NP, nucleus pulpusos; AF, annulus fibrosis; SVF, stromal vascular fraction; VAS, Visual Analog Scale; BDI, Beck Depression Inventory; ODI,
Oswestry Disability Index; PPI, Present Pain Index; SM-MPQ, Short Form McGill Pain Questionnaire; SF-12, Short Form 12.

Autologous PRP

Autologous PRPstromal vascular fraction

Autologous PRP

To assess the efficacy of
single injection of intradisc PRP in patients
with low back pain due
to IDD

Tuakli-Wosornu et
al. [30] (2016)

Autologous PRPBMSC combination.

Composition

To test the efficacy of
PRP‑containing BMSC
on the regeneration of
early IDD

Objective

Wang et al. [29]
(2016)

Study

Table 2. Previous studies documenting the efficacy of intra-disc PRP administration for low back pain
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space infection, neurologic injury, or progressive herniation after receiving the PRP injection.
To summarize, intradiscal PRP injections can be a safe,
cheap, and feasible treatment to counter IVD degeneration associated LBP. It is vital to administer PRP early in
the course of the treatment to stimulate the growth of the
remaining cells in the disc. If the treatment is delayed, the
number of active cells in the disc will be at a minimum
and the PRP will possibly fail to induce the desired impact
[29]. Although intradiscal PRP injections show promising
results, there is a need for more studies with larger sample
sizes and adequate control groups. Further studies are also
needed to define the subset of patients most likely to benefit from this treatment.

Spinal Fusion
Spinal fusion is a procedure used to treat chronic lumbar
pain due to DDD [34]. The procedure involves joining the
vertebrae, to eliminate movement between them, resulting in a continuous bone. The posterolateral fusion of two
adjacent vertebrae is a frequently performed procedure on
the lumbar spine [34,35]. Bone autograft extracted from
the iliac spine is considered to be the gold standard [3436]. The rationale behind this procedure is that the graft
has osteoinductive and osteoconductive properties and
contains osteogenic cells that will result in new bone formation [36].
Harvesting the bone graft can result in serious complications such as donor morbidity, bleeding from the harvest site, nerve injury, and subsequent chronic pain and
infection [34,36-38]. Moreover, the process requires a lot
of time and may still result in inadequate availability of
the graft [34,37].
The use of PRP in spinal fusion surgery could be a possible solution to this problem. TGF-β and PDGF found in
the alpha granules of the concentrated platelets encourage
osteoblast proliferation [34,39-42]. They are a cheap and
natural pool of growth factors that is available instantly in
the operating theater [34,37,40]. They also promise faster
recovery times [40]. Current data available in the literature demonstrate encouraging results.
Landi et al. [40] described 14 patients who underwent
posterolateral fusion. In each patient, PRP along with autologous bone was used on one-half of the operative field
and autologous bone graft alone on the other half. All
patients underwent serial CT scans and plain X-rays at 3
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and 6 months after surgery to evaluate bone fusion. At 3
months, the authors found an increased rate of fusion in
the PRP operated field as compared to the one in which
only the autologous graft was used. Although this difference was balanced out at 6 months, bone density in the
PRP operated field remained higher [40].
A similar finding was reported by Tarantino et al. [34]
in 20 patients who underwent posterolateral arthrodesis
in lumbar spine surgery. In one hemifield, cancellous
bone with PRP was used while in the other cancellous
bone with saline was applied. The results after 6 months
demonstrated a statistically significant increase in bone
density and fusion rates in the PRP hemifield compared to
the half in which cancellous bone alone was used.
Lowery et al. [43] reported a retrospective study of 19
patients with 100% fusion rates who underwent spinal
fusion with the use of autologous growth factors (AGF)
acquired from ultrafiltration of platelets, along with the
bone graft and hydroxyapatite. Similarly, intertransverse
lumbar fusion autograft alone was shown to produce less
bone maturation in comparison with the addition of PRP
to the autograft [44].
Some articles, however, report that PRP has no use in
spinal fusion and some even describe negative outcomes.
Sys et al. [41] investigated the effects of PRP in monosegmental posterior lumbar interbody fusion in 40 patients.
The VAS score and ODI differences between the “allograft
with PRP” group and “allograft only” group were statistically insignificant. Another article demonstrated the
inhibitory effects of AGF used in conjunction with iliac
crest grafts in posterolateral spinal fusion surgery [45].

Intramuscular Injections
The lumbar multifidus (LMF) muscle stabilizes the spine
because of its morphology and its anatomical position.
Its fibers are short with a high cross-sectional area which
supports the muscle’s role in spine stabilization rather
than motion. The relation between lower back pain and
the multifidus muscle has been well established by several
studies [46]. In chronic LBP with monosegmental disc degeneration, the size and cross-sectional area of the muscle
decreases [46].
We found one study that reports the role of platelet leukocyte rich plasma (PLRP) injections on LMF muscle [46].
PLRP intramuscular injections were given to 115 patients
and the outcomes were monitored using the Numeric Rat-

124 Mirza Zain Baig et al.
ing Scale and ODI. Both scores showed a statistically significant improvement. The overall successful outcome was
71.2%, thus demonstrating that PLRP injections in the
LMF muscle can possibly prove to be a safer and cheaper
approach to treat LBP. The lack of a control group, however, limits further decisive conclusions.

Limitations of Platelet-Rich Plasma
The premature release of growth factors through degranulation, the fact that growth factors are released for a shorter duration of time after activation, and their susceptibility
to proteolytic enzymes may render PRP ineffective [35,37].
Variable concentrations and quality of PRP because of
the differences between individuals also limit its use and
contributes to some of the negative results published.
Lastly, the optimal time for PRP implantation, the optimal
concentration of platelets in the PRP sample and whether
PRP should be used in the inactivated or activated form is
yet to be established [35,39].

Conclusions
In conclusion, the use of PRP in various injections, such
as intrafacet, intraligament, epidural, intradiscal, spinal
fusion, and intramuscular injections, has yielded promising results that have been reported in recent literature.
However, further studies are required with larger sample
sizes and control groups to prove its efficacy and establish
its routine use in surgery. The stage of LBP at which PRP
provides the most advantage and how PRP injections
perform in comparison to conservative measures such as
NSAIDS and physiotherapy are also areas for further investigation.
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